Evidence map›Paper›PMID 41981912›Full record

ArticleHGG advances2026

Biallelic variants in CHCHD4 are associated with combined OXPHOS defect leading to mitochondrial disease.

Matthieu Mantecon, Cerina Chhuon, Kevin Roger, Ida Chiara Guerrera, Christine Bole, Patrick Nitschke, Claire-Marie Dufeu-Bérat, Margaret Ashcroft, Robert W Taylor, Nathalie Boddaert and 1 more

Abstract readCase Reports
In one paragraph

Article in HGG advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Matthieu ManteconUniversité Paris Cité, Institut Imagine, Genetics of Mitochondrial Diseases, INSERM UMR, 1163 Paris, France.
Cerina ChhuonProteomics Platform Necker, Université Paris Cité-Structure Fédérative de Recherche Necker, INSERM US24/CNRS UAR3633, 75015 Paris, France.
Kevin RogerProteomics Platform Necker, Université Paris Cité-Structure Fédérative de Recherche Necker, INSERM US24/CNRS UAR3633, 75015 Paris, France.
Ida Chiara GuerreraProteomics Platform Necker, Université Paris Cité-Structure Fédérative de Recherche Necker, INSERM US24/CNRS UAR3633, 75015 Paris, France.
Christine BoleUniversité Paris Cité, Institut Imagine, Genomics Platform, 75015 Paris, France.
Patrick NitschkeUniversité Paris Cité, Institut Imagine, Bioinformatic Platform, 75015 Paris, France.
Claire-Marie Dufeu-BératDepartments of Pediatrics, Hôpital Necker-Enfants Malades, AP-HP, Université Paris Cité, 75015 Paris, France.
Margaret AshcroftUniversity of Cambridge, Department of Medicine, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0QQ, UK.
Robert W TaylorMitochondrial Research Group, Clinical and Translational Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK; NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK.
Nathalie BoddaertPediatric Radiology Department, AP-HP, Hôpital Necker Enfants Malades, Université Paris Cité and Institut Imagine INSERM U1163, 75015 Paris, France.
Agnès RötigUniversité Paris Cité, Institut Imagine, Genetics of Mitochondrial Diseases, INSERM UMR, 1163 Paris, France. Electronic address: agnes.rotig@inserm.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitochondrial disorders show remarkable clinical and genetic heterogeneity and result from variants in either mitochondrion- or nucleus-encoded genes. CHCHD4 is a component of the mitochondrial import and assembly pathway that imports small cysteine-containing substrates. We report a pediatric patient with biallelic CHCHD4 variants who presented with severe neurological regression and early death. Western blot analysis showed decreased levels of CHCHD4 and diminished assembly of complexes I and IV in his fibroblasts. To demonstrate that CHCHD4 variants were responsible for the observed biochemical phenotype, we overexpressed wild-type CHCHD4 in control and subject fibroblasts, restoring levels of complex I and IV proteins and the associated assembly defects. Proteomic studies pointed to electron transport and complex I biogenesis as the main dysregulated pathways and showed a severe loss of several complex I and IV proteins and/or assembly factors rescued by overexpression of wild-type CHCHD4. CHCHD4 has numerous targets and interacting factors and is involved in the export of iron-sulfur clusters synthesized inside mitochondria. Surprisingly, few of these interacting factors or non-mitochondrial functions were impacted by the observed CHCHD4 defect. In conclusion, our work establishes CHCHD4 deficiency as a cause of dysregulated mitochondrial protein import resulting in a severe neurological condition.

Indexed as

AllelesMitochondrial DiseasesMitochondrial ProteinsMutationOxidative PhosphorylationTranscription FactorsFibroblastsHumansMaleMitochondriaMitochondrial Precursor Protein Import Complex ProteinsCHCHD4 protein, humanMitochondrial Precursor Protein Import Complex ProteinsMitochondrial ProteinsTranscription FactorsCHCHD4MIA pathwaymitochondriamitochondrial import and assemblyOXPHOS defect

Identifiers

PMID41981912
PMCPMC13147372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.